Although this study included a limited number of patients, it suggests that evaluating CD8+ T cell tumor infiltration alone, without any transcriptomics analysis or genomic profiling, may serve as a useful biomarker to help decide the treatment method choice and predict the therapeutic response to drug therapy in HCC. The gene discussed is CD8A; the disease is hepatocellular carcinoma.